X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (21453) 21453
Dissertation (170) 170
Book Chapter (144) 144
Conference Proceeding (39) 39
Magazine Article (19) 19
Publication (18) 18
Paper (7) 7
Web Resource (7) 7
Book / eBook (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9182) 9182
arterial hypertension (7795) 7795
arterial-hypertension (5927) 5927
male (5871) 5871
female (5220) 5220
pulmonary hypertension (5040) 5040
pulmonary arterial hypertension (4872) 4872
cardiac & cardiovascular systems (4051) 4051
middle aged (3846) 3846
hypertension (3432) 3432
adult (3222) 3222
animals (2673) 2673
respiratory system (2506) 2506
pulmonary arterial-hypertension (2339) 2339
aged (2260) 2260
hypertension, pulmonary - physiopathology (2093) 2093
risk factors (1863) 1863
hypertension, pulmonary - drug therapy (1604) 1604
disease (1522) 1522
peripheral vascular disease (1518) 1518
medicine, general & internal (1497) 1497
echocardiography (1479) 1479
diagnosis (1465) 1465
survival (1449) 1449
blood pressure (1445) 1445
pharmacology & pharmacy (1318) 1318
therapy (1302) 1302
rats (1298) 1298
treatment outcome (1247) 1247
hypertension, pulmonary - etiology (1196) 1196
mortality (1178) 1178
prevalence (1153) 1153
prognosis (1152) 1152
antihypertensive agents - therapeutic use (1137) 1137
blood-pressure (1119) 1119
hypertension - physiopathology (1099) 1099
hypertension, pulmonary - diagnosis (1079) 1079
care and treatment (1077) 1077
heart (1019) 1019
hemodynamics (971) 971
abridged index medicus (963) 963
diseases of the circulatory system (953) 953
research (948) 948
pulmonary arteries (923) 923
analysis (890) 890
expression (867) 867
hypertension - drug therapy (867) 867
retrospective studies (861) 861
management (841) 841
medicine & public health (823) 823
adolescent (821) 821
bosentan (809) 809
heart failure (801) 801
health aspects (771) 771
inflammation (749) 749
sildenafil (744) 744
physiology (739) 739
medicine, research & experimental (732) 732
guidelines (730) 730
cardiovascular (725) 725
disease models, animal (721) 721
cardiology (712) 712
heart-failure (712) 712
hypoxia (704) 704
hypertension - complications (698) 698
prospective studies (661) 661
children (659) 659
systemic sclerosis (659) 659
hypertension, pulmonary - pathology (653) 653
young adult (651) 651
double-blind (646) 646
medicine (646) 646
pediatrics (641) 641
hypertension, pulmonary - metabolism (637) 637
time factors (637) 637
follow-up studies (633) 633
hypertension, pulmonary - complications (633) 633
smooth-muscle-cells (627) 627
child (623) 623
pulmonary artery - physiopathology (613) 613
blood pressure - drug effects (610) 610
internal medicine (609) 609
surgery (605) 605
mice (604) 604
nitric oxide (603) 603
obesity (601) 601
risk (599) 599
hypertension, pulmonary - therapy (597) 597
rheumatology (585) 585
familial primary pulmonary hypertension (581) 581
scleroderma (580) 580
pressure (564) 564
severity of illness index (559) 559
critical care medicine (539) 539
patients (538) 538
drug therapy (535) 535
hypertrophy (519) 519
cell biology (511) 511
fibrosis (508) 508
cardiovascular disease (504) 504
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (16672) 16672
Russian (2132) 2132
Spanish (880) 880
German (685) 685
French (551) 551
Portuguese (298) 298
Polish (291) 291
Japanese (131) 131
Chinese (89) 89
Czech (84) 84
Italian (75) 75
Slovak (55) 55
Turkish (24) 24
Korean (18) 18
Slovenian (16) 16
Lithuanian (13) 13
Croatian (11) 11
Ukrainian (9) 9
Belarusian (8) 8
Hungarian (5) 5
Serbian (5) 5
Persian (3) 3
Romanian (3) 3
Azerbaijani (2) 2
Arabic (1) 1
Latvian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Chest, ISSN 0012-3692, 03/2016, Volume 149, Issue 3, pp. 660 - 666
BACKGROUND: Evidence-based guidelines recommend the use of parenteral prostaglandin (PP) therapy in patients with advanced pulmonary arterial hypertension... 
Quality improvement | Pulmonary arterial hypertension | Pulmonary hypertension | SURVIVAL | SILDENAFIL | PULMONARY ARTERIAL-HYPERTENSION | pulmonary hypertension | PROSTACYCLIN | CONTINUOUS INTRAVENOUS EPOPROSTENOL | FAILURE | THERAPY | RESPIRATORY SYSTEM | quality improvement | pulmonary arterial hypertension | REGISTRY | INSIGHTS | BOSENTAN | CRITICAL CARE MEDICINE | Guideline Adherence - statistics & numerical data | Humans | Middle Aged | Familial Primary Pulmonary Hypertension - drug therapy | Male | Cause of Death | Patient Selection | Adult | Female | Hypertension, Pulmonary - drug therapy | Phosphodiesterase 5 Inhibitors - therapeutic use | Retrospective Studies | Heart Failure - mortality | Severity of Illness Index | Hypertension, Pulmonary - mortality | Prostaglandins - therapeutic use | Tertiary Care Centers | Comorbidity | Infusions, Parenteral | Death, Sudden | Heart Defects, Congenital - complications | Familial Primary Pulmonary Hypertension - mortality | Quality Improvement | HIV Infections - complications | Endothelin Receptor Antagonists - therapeutic use | Hypertension, Pulmonary - etiology | Connective Tissue Diseases - complications | Cohort Studies | Practice Guidelines as Topic | Care and treatment | Dosage and administration | Patient outcomes | Prostanoids | Original Research | REVEAL, Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management | PAH-PP, patients with pulmonary arterial hypertension treated with parenteral prostaglandin | PAH-nonPP, patients with pulmonary arterial hypertension not treated with parenteral prostaglandin | PH, pulmonary hypertension | PAH, pulmonary arterial hypertension | PP, parenteral prostaglandin | WHO, World Health Organization | Pulmonary Vascular Disease | NYHA, New York Heart Association
Journal Article
Chest, ISSN 0012-3692, 2016, Volume 149, Issue 5, pp. 1234 - 1244
Background In recent years, the population of patients with pulmonary arterial hypertension (PAH) has changed dramatically, including more advanced age at... 
Pulmonary/Respiratory | outcomes | pulmonary arterial hypertension | pulmonary hypertension | age | Pulmonary arterial hypertension | Age | Outcomes | Pulmonary hypertension | 5 INHIBITOR THERAPY | REGISTRIES | HEART-FAILURE | PRESERVED EJECTION FRACTION | RANDOMIZED CONTROLLED-TRIAL | TADALAFIL | ENDOTHELIN RECEPTOR ANTAGONIST | 6-MINUTE WALK | RESPIRATORY SYSTEM | ORAL TREPROSTINIL | EPIDEMIOLOGY | CRITICAL CARE MEDICINE | Multivariate Analysis | Age Factors | Vasodilator Agents - therapeutic use | Humans | Middle Aged | Pulmonary Wedge Pressure | Male | Treatment Outcome | Antihypertensive Agents - therapeutic use | Randomized Controlled Trials as Topic | Epoprostenol - therapeutic use | Epoprostenol - analogs & derivatives | Phenotype | Female | Aged | Hypertension, Pulmonary - drug therapy | Tadalafil - therapeutic use | Walk Test | Hypertension, Pulmonary - etiology | Connective Tissue Diseases - complications | Care and treatment | Prognosis | Aged patients | Research | Health aspects | Causes and theories of causation | Diseases | PAWP, pulmonary artery wedge pressure | FREEDOM-C2 (F-C2), Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension | S+T, SC-TRE and TRUST | TRIUMPH, Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension | ERA, endothelin receptor antagonists | Original Research | PHIRST, Pulmonary Arterial Hypertension and Response to Tadalafil | SC-TRE, Subcutaneous Infusion of Treprostinil in Patients with PAH | PVR, pulmonary vascular resistance | REVEAL, Registry to Evaluate Early and Long-term PAH Disease Management | PH, pulmonary hypertension | PAH, pulmonary arterial hypertension | WHO, World Health Organization | Pulmonary Vascular Disease | 6MWD, 6-min walk distance | or PDE-5I for the Treatment of PAH | COMPERA, Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension | PDE-5I, phosphodiesterase type 5 inhibitors | TRUST, Study of Intravenous Remodulin in Patients in India with PAH | FREEDOM-M (F-M), Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension | mPAP, mean pulmonary artery pressure | CTD, connective tissue disease | FREEDOM-C (F-C), Oral Treprostinil in Combination With an ERA and
Journal Article
Journal of Cardiovascular Pharmacology, ISSN 0160-2446, 06/2019, Volume 73, Issue 6, pp. 383 - 393
Journal Article
by Rhodes, Christopher J and Batai, Ken and Bleda, Marta and Haimel, Matthias and Southgate, Laura and Germain, Marine and Pauciulo, Michael W and Hadinnapola, Charaka and Aman, Jurjan and Girerd, Barbara and Arora, Amit and Knight, Jo and Hanscombe, Ken B and Karnes, Jason H and Kaakinen, Marika and Gall, Henning and Ulrich, Anna and Harbaum, Lars and Cebola, Inês and Ferrer, Jorge and Lutz, Katie and Swietlik, Emilia M and Ahmad, Ferhaan and Amouyel, Philippe and Archer, Stephen L and Argula, Rahul and Austin, Eric D and Badesch, David and Bakshi, Sahil and Barnett, Christopher and Benza, Raymond and Bhatt, Nitin and Bogaard, Harm J and Burger, Charles D and Chakinala, Murali and Church, Colin and Coghlan, John G and Condliffe, Robin and Corris, Paul A and Danesino, Cesare and Debette, Stéphanie and Elliott, C Gregory and Elwing, Jean and Eyries, Melanie and Fortin, Terry and Franke, Andre and Frantz, Robert P and Frost, Adaani and Garcia, Joe G N and Ghio, Stefano and Ghofrani, Hossein-Ardeschir and Gibbs, J Simon R and Harley, John and He, Hua and Hill, Nicholas S and Hirsch, Russel and Houweling, Arjan C and Howard, Luke S and Ivy, Dunbar and Kiely, David G and Klinger, James and Kovacs, Gabor and Lahm, Tim and Laudes, Matthias and Machado, Rajiv D and MacKenzie Ross, Robert V and Marsolo, Keith and Martin, Lisa J and Moledina, Shahin and Montani, David and Nathan, Steven D and Newnham, Michael and Olschewski, Andrea and Olschewski, Horst and Oudiz, Ronald J and Ouwehand, Willem H and Peacock, Andrew J and Pepke-Zaba, Joanna and Rehman, Zia and Robbins, Ivan and Roden, Dan M and Rosenzweig, Erika B and Saydain, Ghulam and Scelsi, Laura and Schilz, Robert and Seeger, Werner and Shaffer, Christian M and Simms, Robert W and Simon, Marc and Sitbon, Olivier and Suntharalingam, Jay and Tang, Haiyang and Tchourbanov, Alexander Y and Thenappan, Thenappan and Torres, Fernando and Toshner, Mark R and Treacy, Carmen M and Vonk Noordegraaf, Anton and Waisfisz, Quinten and Walsworth, Anna K and ... and US PAH Biobank Consortium and UK PAH Cohort Study Consortium and UK NIHR BioResource Rare Diseases Consortium and UK NIHR Bioresource Rare Dis Conso
The lancet respiratory medicine, ISSN 2213-2600, 2019, Volume 7, Issue 3, pp. 227 - 238
Journal Article
The Journal of Pediatrics, ISSN 0022-3476, 08/2019, Volume 211, pp. 63 - 71.e6
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2019, Volume 116, Issue 26, pp. 13122 - 13130
Journal Article
Chest, ISSN 0012-3692, 2009, Volume 135, Issue 3, pp. 794 - 804
Pulmonary arterial hypertension (PAH) is a deadly disease in which vasoconstriction and vascular remodeling both lead to a progressive increase in pulmonary... 
Pulmonary vascular resistance | Right ventricle | Pulmonary arterial hypertension
Journal Article
Journal Article
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2013, Volume 62, Issue 25, pp. D34 - D41
Journal Article